Atelectasis Complicating Acute Poliomyelitis With Involvement of Respiratory Muscles

Cooperstock, Moses

doi:10.1001/archpedi.1944.02020060030004

Cited by 4 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Virtually, all ALS patients experience weakness of the respiratory muscles, both those of the chest wall and the diaphragm, leading to respiratory failure (64). In neuromuscular respiratory failure, patients' lungs are repeatedly underinflated, causing alveolar hypoventilation and chronic microatelectasis (58, [65][66][67]. IL6 is released in local hypoxic conditions (59), such as atelectasis, and is associated with injury even in non-atelectatic lung regions, worsening parenchymal loss (60).…”

Section: Discussionmentioning

confidence: 99%

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients

Wosiski‐Kuhn

Caress

Cartwright

et al. 2020

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

View full text Add to dashboard Cite

Interleukin-6 (IL6) expression increases in atrophying muscles and lung tissue during compromised function. Considering ALS patients undergo these same pathological changes, IL6 levels may be relevant for prognostication and treatment. The amount of soluble IL6 receptor, dictated by the IL6R 358 Ala variant, and local tissue environment in which IL6 signaling occurs is known to influence the ultimate effects of IL6 in multiple diseases. In this longitudinal study, we show that serum IL6 levels negatively correlate both with the patient's functional status as measured by the overall ALSFRS-R and subscores, and with respiratory function as measured by the percent predicted FVC (ppFVC). The correlations are only present in the two-thirds of patients who carry the IL6R 358 Ala variant that mediates proinflammatory transsignaling in the cases of ALSFRS-R limb and respiratory subscores and ppFVC. These results suggest that some observed associations between IL6 and ALS are driven by the subset of patients carrying the IL6R 358 Ala variant and thus that any IL6-targeted therapeutic approaches may be more advantageous when aimed at this group. Specifically, with relation to respiratory decline, these patients may benefit from closer respiratory follow-up and early initiation of noninvasive ventilation.

show abstract

Section: Discussionmentioning

confidence: 99%

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients

Wosiski‐Kuhn

Caress

Cartwright

et al. 2020

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

View full text Add to dashboard Cite

show abstract

Progress in Orthopedic Surgery for 1944 a Review Prepared by an Editorial Board of the American Academy of Orthopaedic Surgeons

Irwin¹

1945

Arch Surg

View full text Add to dashboard Cite

Atelectasis in Poliomyelitis

Morrow

Stimson

1947

Medical Clinics of North America

View full text Add to dashboard Cite

Atelectasis Complicating Acute Poliomyelitis With Involvement of Respiratory Muscles

Cited by 4 publications

References 6 publications

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients

Progress in Orthopedic Surgery for 1944 a Review Prepared by an Editorial Board of the American Academy of Orthopaedic Surgeons

Atelectasis in Poliomyelitis

Contact Info

Product

Resources

About

Atelectasis Complicating Acute Poliomyelitis With Involvement of Respiratory Muscles

Cited by 4 publications

References 6 publications

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients

Progress in Orthopedic Surgery for 1944 a Review Prepared by an Editorial Board of the American Academy of Orthopaedic Surgeons

Atelectasis in Poliomyelitis

Contact Info

Product

Resources

About

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients

Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R³⁵⁸Ala variant groups in amyotrophic lateral sclerosis patients